- Home
- SCPQ vs AGEN Comparison
SCPQ vs AGEN Comparison
Compare SCPQ & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SCPQ | AGEN |
|---|---|---|
| Founded | 2025 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 135.5M | 126.2M |
| IPO Year | N/A | 1999 |
Fundamental Metrics
Financial Performance| Metric | SCPQ | AGEN |
|---|---|---|
| Price | $9.90 | $3.24 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 842.0 | ★ 507.9K |
| Earning Date | 01-01-0001 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $42,877,086.00 |
| Revenue This Year | N/A | $61.42 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $8.89 |
| Revenue Growth | N/A | ★ 89.95 |
| 52 Week Low | $9.86 | $1.38 |
| 52 Week High | $9.95 | $7.34 |
Technical Indicators
Market Signals| Indicator | SCPQ | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 46.15 |
| Support Level | N/A | $2.91 |
| Resistance Level | N/A | $3.26 |
| Average True Range (ATR) | 0.00 | 0.27 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 0.00 | 27.54 |
Price Performance
Historical ComparisonAbout SCPQ Social Commerce Partners Corporation Class A Ordinary Shares
Social Commerce Partners Corp is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).